Нестероидные противовоспалительные препараты и ацетилсалициловая кислота. Есть ли нерешенные вопросы?

1. Насонов Е.Л. Нестероидные противовоспалительные препараты: Перспективы применения в медицине. М.: Анко, 2000.
2. Насонов Е.Л. Специфические ингибиторы ЦОГ-2: решенные и нерешенные проблемы. Клин. фармакология и терапия. 2000; 1: 57–64.
3. Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: ИМА-ПРЕСС, 2009.
4. FitzGerald GA, Patrono C. The Coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433–42.
5. McAdam BF, Catella-Lawson F, Mardini IA et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitors of COX-2. PNAS 1999; 96: 272–7.
6. Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease. A reappraisal. Arthritis Rheum 2003; 48: 12–20.
7. Marcus AJ, Broekman MJ, Pinsky GJ. COX inhibition and thromboregulation. N Engl J Med 2002; 347: 1025–6.
8. White WB, Faich G, Whelton A et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase–2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425–30.
9. Konstam MA, Weir AR. Current persective on the cardiovascular effects of coxibs. Clev Clin J Med 2002; Suppl. 1: 47–52.
10. Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum (Arthritis Care & Res) 2002; 47: 349–55.
11. White WB, Faich G, Borer JS, Makuch R. Cardiovascular thrombotic events are not increased on the cyclooxygenase-2 inhibitor – celecoxib. ACR 66th Annual Scientific Meeting, New Orleans 2002; 485.
12. Reicin AS, Shapiro D, Sperlong RS et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory druds (ibuprofen, diclofenac and nabumeton). Am Cardiol 2002; 89: 204–9.
13. Singh GS, Garnier P, Hwang E et al. Meloxicam does not increase the risk of cardiovascular adverse events compared to other NSAIDs: results from the IMPROVE trial, a multi-center, randomized parallel-group, open label study of 1309 patients in a managed case setting. EULAR Annual Congress of Rheumatology, Stockholm. Sweden, THU0259 (abst).
14. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 2007; 22; 370 (9605): 2138–51.
15. Singh G, Graham D, Wang H et al. Concominant aspirin use reduces the risk of acute myocardial infarction in users of cyclooxygenase-2 selective and some non-selective nonsteroidal anti-inflammatory drugs. Ann Rheum Dis 2006; 65 (Suppl. II): 61.
16. Knijff-Dutmer EAJ, Kalsbeek-Batenburg EM, Koerts J, van Laar MAFJ. Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology 2002; 41: 458–61.
17. Сatella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effect of aspirin. N Engl J Med 2001; 345: 1809–17.
18. Van Solingen RM, Rosenstein ED, Mihailescu G et al. Comparison of the effects of ketoprofen on platelet function in the presence and absence of aspirin. Am J Med 2001; 111: 285–9.
19. Ouellett M, Riendeau D, Percival D. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced intereference of platelet cyclooxygenase-1 inactivation by aspirin. PNAS 2001; 98: 14583–8.
20. Greenberg H, Gottesdiener K, Huntington M et al. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharm 2000; 40: 1509–15.
21. Derry S, Loke YK. Risk of gastrointestinal haemorrage with long term use of aspirin. BMJ 2000; 321: 1183–7.
22. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecocib for treatment of osteoarthritis and rheumatoid arthritis: systemic review of randomized controlled trials. BMJ 2002; 325: 1–8.
23. Goldstein H, Bello A, Fort J et al. Differential rates of UGI symptoms in patients receiving celecoxib vs rofecoxib with and without low-dose aspirin for cardiovascular prophylaxis. EULAR Annual Congress of Rheumatology, Stockholm. Sweden, THU0246 (abst).
24. Singh G, Goldstein J, Bello A et al. Efect of concurrent low-dose aspirin use on the incidence of UGI symptoms in patients receiving celecoxib or conventional NSAIDs: analysis of two largr randomized, double-blind controlled clinical studies. 2002 EULAR Annual Congress of Rheumatology, Stockholm. Sweden, THU0267 (abst).
25. Chenevard R, Hurlimann D, Bechir M et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003; 107.
26. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115–26.
27. Tousoulis D, Davies G, Stefanadis et al. CInflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 2003; 89: 993–7.
28. Baker CS, Hall RJ, Evans TJ et al. Cyclooxygenase 2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalized with inducible nitric oxide synthase and nitrotyrosine particularly macrophages. Atheroscler Thromb Vasc Biol 1999; 19: 646–55.
29. Schonbeck U, Sukhova GK, Graber P et al. Augmented expression of cyclooxigenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281–91.
30. Burleigh ME, Babaev VR, Oates JA et al. Cyclooxygenase 2 promotes early atherosclerotic lesion formation in LDL receptor deficiency mice. Circulation 2002; 105: 1816–23.
31. Cippilone F, Prontera C, Pini B et al. Overexpression of functionally coupled cyclooxygenase Esynthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2–dependent plaque instability. Circulation 2001; 104: 921–30.
32. Belton O, Byrne D, Kearney D et al. Cyclooxygenase-1 and – 2 dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840–5.

А.В.Родионов 

ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ